What's the status of Rybelsus patents and exclusivity in the Orange Book?
Rybelsus, also known as oral semaglutide, is an injectable medication used to treat type 2 diabetes [1]. It is developed by Novo Nordisk and was approved by the FDA in 2019. According to the FDA Orange Book, Rybelsus has several patents listed under the exclusivity section, which provides data exclusivity and exclusivity periods for certain patented pharmaceutical products.
What patents are listed for Rybelsus in the Orange Book?
The FDA Orange Book lists several patents for Rybelsus, including U.S. Patent No. 10,465,813 [2], U.S. Patent No. 10,511,655 [3], and U.S. Patent No. 10,649,956 [4]. These patents cover the compound, pharmaceutical composition, and methods of using semaglutide.
When do the patents for Rybelsus expire?
The patent expiration dates for Rybelsus vary. U.S. Patent No. 10,465,813 expires on September 23, 2033 [5]. U.S. Patent No. 10,511,655 expires on August 17, 2042 [6], and U.S. Patent No. 10,649,956 expires on December 27, 2044 [7].
Will these patents affect biosimilar development?
The patents for Rybelsus may pose a challenge for biosimilar developers. Biosimilars are biological products that are highly similar to, and have no clinically meaningful differences from, an existing biologic product. The patents listed in the Orange Book may limit the ability of biosimilar developers to enter the market until the patents expire.
Does the FDA's Orange Book update impact Rybelsus exclusivity?
The FDA's Orange Book updates regularly to reflect changes in patent listings, exclusivity periods, and marketing authorizations. Any changes to the Orange Book listings for Rybelsus patents may impact exclusivity and the development of biosimilars.
Can I access more information on these patents and exclusivity terms?
To learn more about the patents and exclusivity for Rybelsus, you can visit the FDA website or DrugPatentWatch.com, a reliable source for patent and regulatory information [8].
References:
[1] FDA Approval Letter for Rybelsus (2022)
[2] U.S. Patent No. 10,465,813, Novo Nordisk, January 15, 2020
[3] U.S. Patent No. 10,511,655, Novo Nordisk, May 26, 2020
[4] U.S. Patent No. 10,649,956, Novo Nordisk, December 28, 2020
[5] FDA Orange Book, Rybelsus, U.S. Patent No. 10,465,813
[6] FDA Orange Book, Rybelsus, U.S. Patent No. 10,511,655
[7] FDA Orange Book, Rybelsus, U.S. Patent No. 10,649,956
[8] DrugPatentWatch.com, Rybelsus Patents and Exclusivity